We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
-2.45%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$364M
AUM Growth
-$19.7M
Cap. Flow
-$6.77M
Cap. Flow %
-1.86%
Top 10 Hldgs %
44.42%
Holding
83
New
22
Increased
23
Reduced
12
Closed
26

Top Buys

Rank Stock Value
1
CI icon
Cigna
CI
+$17.9M
2
ICLR icon
Icon
ICLR
+$17.1M
3
TMO icon
Thermo Fisher Scientific
TMO
+$14M
4
THC icon
Tenet Healthcare
THC
+$13.5M
5
RCM
R1 RCM Inc. Common Stock
RCM
+$10.6M

Top Sells

Rank Stock Value
1
KIDS icon
OrthoPediatrics
KIDS
+$19.3M
2
AHCO icon
AdaptHealth
AHCO
+$14.7M
3
SNY icon
Sanofi
SNY
+$13.5M
4
BDX icon
Becton Dickinson
BDX
+$13.2M
5
CVS icon
CVS Health
CVS
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 80.17%
2 Industrials 3.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LH icon
1
Labcorp
LH
$25B
$17.4M 4.77%
73,238
+20,597
+39% +$4.69M
CI icon
2
Cigna
CI
$73.7B
$17M 4.68%
+71,856
New +$17.9M
ICLR icon
3
Icon
ICLR
$12.6B
$16.4M 4.51%
+79,415
New +$17.1M
TMO icon
4
Thermo Fisher Scientific
TMO
$213B
$15M 4.12%
+29,679
New +$14M
THC icon
5
Tenet Healthcare
THC
$20.5B
$14.6M 4.01%
+217,891
New +$13.5M
RCM
6
DELISTED
R1 RCM Inc. Common Stock
RCM
$12.2M 3.36%
548,876
+440,630
+407% +$10.6M
SYNH
7
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$11.7M 3.2%
130,238
+24,717
+23% +$2.09M
IVC
8
DELISTED
Invacare Corporation
IVC
$11.1M 3.05%
1,374,840
+267,728
+24% +$2.23M
ABBV icon
9
AbbVie
ABBV
$443B
$9.63M 2.65%
85,514
-2,468
-3% -$278K
ELUT icon
10
Elutia
ELUT
$37.9M
$8.39M 2.31%
873,159
+289,559
+50% +$3.34M
OCUL icon
11
Ocular Therapeutix
OCUL
$1.79B
$8.1M 2.23%
570,970
+132,037
+30% +$2.01M
PHAS
12
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$7.92M 2.18%
2,129,709
-33,809
-2% -$113K
HAE icon
13
Haemonetics
HAE
$3.89B
$7.86M 2.16%
117,904
+102,765
+679% +$7.27M
EAR
14
DELISTED
Eargo, Inc. Common Stock
EAR
$7.72M 2.12%
+9,674
New +$8.11M
BIO icon
15
Bio-Rad Laboratories Class A
BIO
$8.71B
$7.62M 2.09%
11,820
-2,964
-20% -$1.8M
INSM icon
16
Insmed
INSM
$21.4B
$7.41M 2.04%
260,314
+127,892
+97% +$3.8M
HOLX
17
DELISTED
Hologic
HOLX
$7.39M 2.03%
+110,840
New +$7.41M
HUM icon
18
Humana
HUM
$43.7B
$6.99M 1.92%
+15,791
New +$6.9M
BMY icon
19
Bristol-Myers Squibb
BMY
$133B
$6.75M 1.86%
101,081
-132,817
-57% -$8.66M
XRAY icon
20
Dentsply Sirona
XRAY
$2.68B
$6.57M 1.81%
+103,860
New +$6.84M
ADAP
21
DELISTED
Adaptimmune Therapeutics
ADAP
$6.56M 1.8%
1,539,435
+623,724
+68% +$3.03M
MTEM
22
DELISTED
Molecular Templates, Inc.
MTEM
$5.85M 1.61%
49,868
+2,577
+5% +$337K
TRIL
23
DELISTED
Trillium Therapeutics Inc.
TRIL
$5.83M 1.6%
600,788
+122,414
+26% +$1.15M
VCYT icon
24
Veracyte
VCYT
$3.7B
$5.61M 1.54%
+140,211
New +$6M
DRIO icon
25
DarioHealth
DRIO
$70.9M
$5.53M 1.52%
12,939
-2,955
-19% -$1.13M
1
2 3 4

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Endurant Capital Management held 83 positions worth $364M, down 5.1% from $384M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Endurant Capital Management's Q2 2021 filing shows 22 new, 23 increased, 12 reduced and 26 closed positions. Its largest new stake was Cigna: 71,856 shares worth $17M. The largest sale was OrthoPediatrics, an estimated $19.3M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 86% a quarter earlier, followed by Industrials.

  • Endurant Capital Management's largest Q2 2021 buy was Cigna: 71,856 shares worth $17M.
  • Endurant Capital Management added most to R1 RCM Inc. Common Stock in Q2 2021, an estimated $10.6M increase.
  • Endurant Capital Management's biggest Q2 2021 reduction was Bristol-Myers Squibb, cutting an estimated $8.66M.
  • Endurant Capital Management fully exited OrthoPediatrics in Q2 2021, selling an estimated $19.3M.
  • Endurant Capital Management's ten largest holdings make up 44% of its $364M portfolio in Q2 2021.
  • Endurant Capital Management opened 22 new positions and closed 26 in Q2 2021.
  • Endurant Capital Management's portfolio value fell 5.1% quarter-over-quarter to $364M.

Based on Endurant Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.